Oral administration of artemisinin analog SM934 ameliorates lupus syndromes in MRL/lpr mice by inhibiting Th1 and Th17 cell responses.

@article{Hou2011OralAO,
  title={Oral administration of artemisinin analog SM934 ameliorates lupus syndromes in MRL/lpr mice by inhibiting Th1 and Th17 cell responses.},
  author={Li-fei Hou and Shi-jun He and Xin Li and Yang Yang and Pei-lan He and Yu Zhou and Feng-hua Zhu and Yi-fu Yang and Ying Li and Wei Tang and Jian-ping Zuo},
  journal={Arthritis and rheumatism},
  year={2011},
  volume={63 8},
  pages={2445-55}
}
OBJECTIVE SM934, an artemisinin derivative, possesses potent antiproliferative and antiinflammatory properties. The aim of this study was to examine the effects and explore the mechanisms of SM934 to treat autoimmune disease in lupus-prone female MRL/lpr mice. METHODS In vitro, the effects of SM934 on the activation of polyclonal CD4+ T cells and the differentiation of naive CD4+ T cells were examined. In vivo, the preventative or therapeutic effects of SM934 in MRL/lpr mice were investigated… CONTINUE READING